DK3773715T3 - Mirikizumab i behandlingen af colitis ulcerosa - Google Patents

Mirikizumab i behandlingen af colitis ulcerosa Download PDF

Info

Publication number
DK3773715T3
DK3773715T3 DK19722256.5T DK19722256T DK3773715T3 DK 3773715 T3 DK3773715 T3 DK 3773715T3 DK 19722256 T DK19722256 T DK 19722256T DK 3773715 T3 DK3773715 T3 DK 3773715T3
Authority
DK
Denmark
Prior art keywords
mirikizumab
treatment
ulcerative colitis
ulcerative
colitis
Prior art date
Application number
DK19722256.5T
Other languages
Danish (da)
English (en)
Inventor
James Benedict Canavan
Stuart William Friedrich
Kathryn Ann Krueger
Catherine Milch
Jay Lawrence Tuttle
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK3773715T3 publication Critical patent/DK3773715T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK19722256.5T 2018-03-30 2019-03-28 Mirikizumab i behandlingen af colitis ulcerosa DK3773715T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862650314P 2018-03-30 2018-03-30
PCT/US2019/024633 WO2019191464A1 (en) 2018-03-30 2019-03-28 Methods of treating ulcerative colitis

Publications (1)

Publication Number Publication Date
DK3773715T3 true DK3773715T3 (da) 2024-05-27

Family

ID=66429483

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19722256.5T DK3773715T3 (da) 2018-03-30 2019-03-28 Mirikizumab i behandlingen af colitis ulcerosa
DK23215626.5T DK4327866T3 (da) 2018-03-30 2019-03-28 Mirikizumab ved behandling af ulcerøs kolitis

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK23215626.5T DK4327866T3 (da) 2018-03-30 2019-03-28 Mirikizumab ved behandling af ulcerøs kolitis

Country Status (29)

Country Link
US (2) US12152072B2 (https=)
EP (2) EP4327866B1 (https=)
JP (4) JP7119114B2 (https=)
KR (1) KR102552693B1 (https=)
CN (1) CN111936165A (https=)
AU (2) AU2019243283C1 (https=)
BR (1) BR112020018099A2 (https=)
CA (1) CA3095297A1 (https=)
DK (2) DK3773715T3 (https=)
EA (1) EA202091989A1 (https=)
ES (2) ES3063700T3 (https=)
FI (2) FI3773715T3 (https=)
HR (2) HRP20240904T1 (https=)
HU (1) HUE067445T2 (https=)
IL (2) IL277514B2 (https=)
LT (2) LT4327866T (https=)
MA (2) MA67901B1 (https=)
MD (1) MD3773715T2 (https=)
MX (1) MX2020010269A (https=)
MY (1) MY202368A (https=)
PL (2) PL3773715T3 (https=)
PT (2) PT3773715T (https=)
RS (2) RS67806B1 (https=)
SG (1) SG11202009526RA (https=)
SI (1) SI3773715T1 (https=)
TW (2) TWI837532B (https=)
UA (1) UA128578C2 (https=)
WO (1) WO2019191464A1 (https=)
ZA (1) ZA202005388B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CA3170677A1 (en) * 2020-02-14 2021-08-19 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody
KR20230023663A (ko) 2020-05-21 2023-02-17 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법
JP7423815B2 (ja) * 2020-10-20 2024-01-29 セトラスホールディングス株式会社 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム
JP2024501900A (ja) * 2021-01-06 2024-01-16 アッヴィ・インコーポレイテッド クローン病及び潰瘍性大腸炎を処置する方法
EP4340875A1 (en) * 2021-05-20 2024-03-27 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
JP2024521748A (ja) * 2021-05-28 2024-06-04 イーライ リリー アンド カンパニー 潰瘍性大腸炎に関与する遺伝子の抗il-23p19抗体調節
WO2023095000A1 (en) * 2021-11-23 2023-06-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
US20240199734A1 (en) * 2022-11-22 2024-06-20 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
KR20250156783A (ko) 2023-03-10 2025-11-03 일라이 릴리 앤드 캄파니 궤양성 결장염을 치료하는 방법
CN121443635A (zh) * 2023-06-16 2026-01-30 信达生物医药科技(杭州)有限公司 重组抗白介素23p19亚基抗体在治疗炎症性肠病中的用途
WO2025170982A2 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2026060205A1 (en) 2024-09-13 2026-03-19 Eli Lilly And Company PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006265002B2 (en) * 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
SI1971366T1 (sl) 2005-12-29 2014-10-30 Janssen Biotech, Inc. Humana protitelesa anti-il-23, sestavki, postopki in uporabe
AR065420A1 (es) 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
US20110212104A1 (en) * 2008-11-03 2011-09-01 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PE20141162A1 (es) * 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
CA3092551A1 (en) * 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody

Also Published As

Publication number Publication date
EP4327866A2 (en) 2024-02-28
JP7331219B2 (ja) 2023-08-22
AU2019243283B2 (en) 2023-07-27
JP2025020134A (ja) 2025-02-12
HUE067445T2 (hu) 2024-10-28
AU2023248103B2 (en) 2026-02-05
IL277514B2 (en) 2024-11-01
JP7119114B2 (ja) 2022-08-16
HRP20260275T1 (hr) 2026-04-10
TWI744617B (zh) 2021-11-01
IL312807B1 (en) 2025-02-01
PT4327866T (pt) 2026-02-17
ES3063700T3 (en) 2026-04-20
TW202206104A (zh) 2022-02-16
SI3773715T1 (sl) 2024-06-28
BR112020018099A2 (pt) 2020-12-22
IL312807B2 (en) 2025-06-01
TW201946657A (zh) 2019-12-16
US20210032325A1 (en) 2021-02-04
IL312807A (en) 2024-07-01
EP4327866A3 (en) 2024-03-20
ES2983809T3 (es) 2024-10-24
CA3095297A1 (en) 2019-10-03
IL277514B1 (en) 2024-07-01
RS67806B1 (sr) 2026-03-31
ZA202005388B (en) 2025-05-28
PL3773715T3 (pl) 2024-08-19
DK4327866T3 (da) 2026-02-23
HRP20240904T1 (hr) 2024-10-11
KR20200128101A (ko) 2020-11-11
PT3773715T (pt) 2024-05-27
US12152072B2 (en) 2024-11-26
EP4327866B1 (en) 2025-12-10
JP7571225B2 (ja) 2024-10-22
FI3773715T3 (fi) 2024-05-30
JP2023166388A (ja) 2023-11-21
LT3773715T (lt) 2024-06-25
RS65661B1 (sr) 2024-07-31
US20250034243A1 (en) 2025-01-30
MY202368A (en) 2024-04-24
EP3773715B1 (en) 2024-05-08
MA52216A (fr) 2021-02-17
CN111936165A (zh) 2020-11-13
AU2019243283A1 (en) 2020-09-24
UA128578C2 (uk) 2024-08-21
AU2019243283C1 (en) 2024-05-02
AU2023248103A1 (en) 2023-11-09
TWI837532B (zh) 2024-04-01
MA67901B1 (fr) 2026-02-27
WO2019191464A1 (en) 2019-10-03
JP2021517156A (ja) 2021-07-15
SG11202009526RA (en) 2020-10-29
MX2020010269A (es) 2020-11-06
KR102552693B1 (ko) 2023-07-07
LT4327866T (lt) 2026-03-10
FI4327866T3 (fi) 2026-02-18
MD3773715T2 (ro) 2024-10-31
IL277514A (en) 2020-11-30
EA202091989A1 (ru) 2021-01-13
JP2022169562A (ja) 2022-11-09
EP3773715A1 (en) 2021-02-17
PL4327866T3 (pl) 2026-04-20
MA52216B1 (fr) 2024-07-31
NZ767902A (en) 2024-05-31

Similar Documents

Publication Publication Date Title
DK3773715T3 (da) Mirikizumab i behandlingen af colitis ulcerosa
HUS2500039I1 (hu) Elafibranor primer biliáris cirrózis kezelésében történõ alkalmazásra
DK3743053T3 (da) Anvendelse af cannabinoider i behandling af epilepsi
DK3641819T3 (da) Anvendelse af cannabidiol i behandling af tuberøst sklerosekompleks
DK3578547T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
DK3562486T3 (da) Anvendelse af sublingual dexmedetomidin til behandling af agitation
DK3117310T3 (da) Håndtering af behandling associeret med valgte arkitektoniske indretninger
DK3490582T3 (da) Sammensætninger til anvendelse i behandling af myelofibrose
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3576738T3 (da) Gaboxadolmonohydrat i behandling af tinnitus
DK3204497T3 (da) Terapeutisk hæmning af lactatdehydrogenase og midler dertil
DK3331879T3 (da) Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3273995T3 (da) Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
DK3331610T3 (da) Midler til anvendelse til behandling af gliom
DK3125874T3 (da) Et terapeutisk middel til anvendelse i behandlingen af infektioner
DK3706739T3 (da) Anvendelse af riluzolprodrugs til behandling af ataksier
DK3535511T3 (da) Reduktion af mikrobiologisk vækst i rør
CY2024037I1 (el) Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων
DK3157532T3 (da) Fremgangsmåder til behandling og forebyggelse af sygdomme med vaskulær instabilitet
DK3442558T3 (da) Bmp-7-afledte peptider til anvendelse i behandlingen af osteoartritis
EP3524175A4 (en) Blood conduit with stent
DK3373922T3 (da) Sammensætninger og fremgangsmåder til anvendelse i behandlingen af homocystinuri